New scan could spot breast cancer type without needle
NCT ID NCT07275463
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a radioactive imaging agent called [99mTc]Tc-DB8 to see if it can help doctors see breast cancer tumors and tell whether they are estrogen receptor positive or negative. Forty women with primary breast cancer will get one injection of the agent, followed by a SPECT/CT scan two hours later. The goal is to find out if this scan can provide useful information about the tumor type, which might guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m-labelled DB8 ([99mTc]Tc-DB8)
What this could lead to
If successful, this could lead to a new imaging method to better identify breast cancer types without invasive biopsies.
What could go wrong
This is a small, early-phase study with only 40 participants, so results may not apply to all patients. The imaging agent is experimental and its accuracy is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Russia Tomsk NRMC
Tomsk, Russia